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PATIENT SATISFACTION COMPARISONS BETWEEN PEDIATRICIANS 
AND OTHER PCPS: A MULTILEVEL CROSS-NATIONAL WEB BASED 
SURVEY STUDY
Chang J1, Patel I1, Feldman SR2, Balrkishnan R1
1University of Michigan at Ann Arbor, Ann Arbor, MI, USA, 2Wake Forest University School 
of Medicine, Winston Salem, NC, USA
OBJECTIVES: Very few studies have tried to evaluate comparative patient ratings of 
physician satisfaction across specialties. We examined the differences in physician 
satisfaction reported by patients accessing care from pediatricians versus other primary 
care physicians. METHODS: We conducted a cross sectional, national web based 
survey study consisting of anonymous patients who rated their physicians on the basis 
of treatment satisfaction that they received from their most recent outpatient visits. 
The survey was user friendly, validated and helped patients identify their physicians 
as per specialties and rate them on a scale of 0 (“not at all satisﬁed”) to 10 (“extremely 
satisﬁed”). The association of physician satisfaction between pediatricians and non-
pediatricians was assessed using hierarchical linear model (HLM). RESULTS: Using 
6982 patient survey responses, we matched 2724 PCP visits with a similar number of 
visits to pediatricians. After controlling other variables, pediatricians were associated 
with higher satisfaction, on average, than other PCPs (r03 = 14.79, p < 0.000). Spending 
time with patients was positively associated with patient satisfaction (r50 = 3.49, p < 
0.000) holding all other factors in the model constant. However, pediatricians were 
associated with lower time spent with patients (r53 = −1.1, p = 0.045). After controlling 
for other variables, waiting time was negatively associated with patient satisfaction 
(r40 = −0.37, p = 0.000). CONCLUSIONS: Our study ﬁnds that pediatricians are 
associated with higher patient satisfaction score than non-pediatricians. Increased time 
spent with the patient by pediatricians convinced to other PCPs to be the driver of 
the effect.
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THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D 
ELECTRONIC VERSION (EQ-5D EPRO)
Ashcroft-Jones AJ1, Furtado T1, Wild D2
1Oxford Outcomes, Oxford, Oxon, UK, 2Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The objective of this study was to produce translations of the ePRO 
version of the EQ-5D that are conceptually equivalent to the original and other lan-
guage versions, ensuring that the resulting translations are suitable for use in the ePRO 
format. METHODS: The methodology employed was: 1 forward and 1 back transla-
tion, review, developer review, linguistic validation interviews with 5 respondents (a 
mix of lay people and patients), second developer review and 2 proofreadings. 
RESULTS: The translation process highlighted numerous issues: 1) ‘Tap’, meaning to 
press lightly on the screen with a stylus, proved problematic in translation. In some 
languages, a literal translation would result in the patient touching the screen too 
lightly, not understanding that pressure was required. In other languages, there was 
no exact translation available. ‘press’ or ‘touch with the stylus’ were used as alterna-
tives (French and Russian respectively), ensuring that patients could navigate the 
platform; 2) In some Romance languages, the emphasis of ‘tap ONE box’, meaning 
only one, became lost due to the languages’ requirement of an article. Some translators 
used a capitalised deﬁnite article (‘THE’), others placed ‘ONLY ONE’ in brackets to 
provide the stress; 3) The Eastern European translators maintained that there is isno 
literal translation of ‘heading’, in the context of a title with sentences underneath. To 
render the intended meaning, they used ‘the text in bold’ or ‘in each of the groups’; 
4) Some languages found ‘Please do this by [. . .]’ a difﬁcult construction to translate 
directly and colloquially. The expression was substituted with ‘You do it by [. . .]’, 
which was more idiomatic. CONCLUSIONS: The EQ-5D ePRO has been translated 
and linguistically validated using a rigorous translation process. A number of cultural 
and linguistic issues became apparent and were resolved. The measure is now appro-
priate for use in multinational trials.
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SUPPLEMENTAL METHODOLOGY FOR TRANSLATING INSTRUMENTS 
DEVELOPED IN A LANGUAGE OTHER THAN ENGLISH
Handa M1, Gawlicki M2, McKown S1, Lauritzen M1, Hasegawa N1
1Corporate Translations, Inc, Chicago, IL, USA, 2Corporate Translations, Inc, East Hartford, 
CT, USA
OBJECTIVES: Procedures used to linguistically validate PROs are well documented 
for instruments originally developed in English. However, methodology concerning 
non-English based measures is largely uncharted. This paper outlines the challenges 
associated with translating PROs developed in a language other than English and 
recommends supplemental methodology for improving this process. METHODS: To 
establish guidelines for translating non-English PROs, several case studies of previous 
validations were performed. Techniques used to validate the Cancer Dyspnoea Scale 
(Japanese) were compared to those used for the Pain Detect Scale (German), DN4 
Questionnaire (French), and the Hôtel Dieu 16 (French). All questionnaires were 
translated from their source language into US English. The DN4 was subsequently 
translated into Dutch, while the CDS was translated into seven additional languages. 
Special attention was paid to maintaining conceptual equivalence, addressing collo-
quialisms native to the development setting and compensating for differing grammati-
cal rules. RESULTS: Linguistically validating non-English PROs poses numerous 
problems. Since most translators and project managers are English-based, an English 
adaptation of the instrument may need to be created prior to moving forward with 
other translations. Extreme care must be taken to accurately interpret all of the source 
instrument’s concepts. Recommended enhancements to the standard validation 
process include: assigning a project manager skilled in the source language to oversee 
all subsequent translations; creating a concept elaboration guide for both the original 
instrument and the English translation; conducting a specialized training session with 
translators to review the development of the original document and the English 
translation; placing extra emphasis on the meaning of colloquialisms and the formula-
tion of response sets. CONCLUSIONS: Linguistically validating PRO questionnaires 
developed in non-English settings presents special challenges. Evidence suggests that, 
in these situations, standard procedures may be insufﬁcient to produce conceptually 
equivalent translations acceptable for use in multinational clinical trials. In such cases, 
expanded procedures are recommended.
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ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF 
EPRO AND IVRS INSTRUMENTS
Gordon-Stables R, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: ePRO and IVRS PRO instruments are increasingly used in clinical 
trials. As a result translations of such instruments are also increasingly required. Whilst 
the approach recommended in the ISPOR translation task force paper (Wild et al. 
2005) should still be used, ePRO and IVRS instruments present some unique chal-
lenges during their translation and linguistic validation. This study seeks to clarify 
what some of those challenges are, and how to meet them. METHODOLOGY: 
Oxford Outcomes translation and linguistic validation projects involving ePRO/IVRS 
were reviewed to produce a list of tips on how best to localise such instruments. 
RESULTS: Give translators information about limited screen size up front to avoid 
shortening strings later in the process. Participants in IVRS studies have to listen to 
the PRO instrument; therefore prompts should not be too long and have too many 
concepts (this helps both translators and participants). Avoid concatenation (where a 
sentence is split in the software coding and put back together at run time). Don’t split 
question stems from the questions. Provide translators with existing translations lever-
aged from previous translation projects to ensure consistency. Ideally cognitive debrief-
ing of the translation should be carried out via the medium of ﬁnal delivery (e.g. if it 
is on a handheld computer, the participants see the instrument on a handheld com-
puter). It is worth having a linguist check ﬁnal translated software/listen to recorded 
prompts—to ensure no errors have been introduced at software building / recording 
stage. CONCLUSIONS: With some forward planning, the challenges of translating 
and validating an ePRO or IVRS instrument can be met, ensuring a translation that 
is conceptually equivalent and suitable for use in the target country with the target 
patient population.
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VALIDITY OF SELF-REPORT WITH RESPECT TO PRESCRIPTION 
MEDICATIONS AMONG PREGNANT WOMEN
Jaiswal P, Sarangarm P, Young B, Khan N, Dodd M, Phelan S, Rayburn W, Bakhireva L
University of New Mexico Health Sciences Center, Albuquerque, NM, USA
OBJECTIVES: Accuracy of self-report regarding prescription medication use among 
pregnant women is largely unknown. Accurate self-reported information is needed for 
medication reconciliation purposes, clinical management, clinical teratology research, 
and monitoring of adherence. This study examines the accuracy of self-reported medi-
cation use by pregnant women for medications used chronically and episodically or 
intermittently during pregnancy. METHODS: This was a cross-sectional analysis of 
data collected through the University of New Mexico (UNM) cohort study, “Safety 
of Medication and Perception of Teratogenicity” (SMART). Pregnant women were 
recruited from UNM prenatal care clinics and were asked to report all medications 
they took since their last menstrual period. The analysis was limited to women enrolled 
in the ﬁrst year of the study who had at least one prescription for diabetes or opioid 
analgesics medications (representative of chronic and acute medication use, respec-
tively). The accuracy of agreement between self-report and medical records for each 
medication class was estimated by simple (κ) and prevalence and bias adjusted 
(PABAK) kappa. Information from the medical records was used as the ‘gold-stan-
dard’. RESULTS: A total of 92 pregnant women were included in the analysis. Agree-
ment for diabetes medications was near perfect (κ = 0.87; PABAK = 0.91); whereas 
poor-to-moderate concordance was observed for opioid analgesics (κ = 0.29; PABAK 
= 0.57). Among antidiabetic medications, concordance was highest for biguanides (κ 
= 0.90; PABAK = 0.93) and lowest for sulfonylureas (κ = 0.83; PABAK = 0.87); 
whereas among opioid analgesics, highest agreement was observed for strong agonists 
(κ = 0.51; PABAK = 0.56) and lowest for moderate/low agonists (κ = 0.06; PABAK 
= 0.59). CONCLUSIONS: This study suggests poor accuracy of self-report with 
respect to prescription medications used as short courses or intermittently during 
pregnancy. Therefore, in clinical studies assessing safety of such medications in preg-
nancy, self-reported information needs to be supplemented by other sources. Accuracy 
of self-report for medications used chronically is acceptable.
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PATIENT REPORTED OUTCOME RECALL PERIODS IN LIGHT OF  
THE FINAL FDA GUIDANCE
Wild D, Nixon A
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The selection of the most appropriate recall periods for PROs has been 
a topic of much debate since the release of the draft FDA PRO guidance in February 
2006. The ﬁnal PRO guidance (December 2009) provides more insight into the way 
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that the FDA will evaluate PRO recall periods. This study reviews the literature around 
PRO recall periods in the light of the ﬁnal guidance and provides recommendations 
to sponsors wishing to obtain FDA label claims on the basis of PRO endpoints. 
METHODS: A literature review was conducted in Embase and Medline, with further 
searching in Google scholar. References from each of the relevant papers were hand 
searched. Forty four papers were reviewed with reference to section D3 of the FDA 
ﬁnal PRO guidance, the research was summarized and a set of recommendations were 
developed. RESULTS: Psychological literature identiﬁes that recall of complex infor-
mation is problematic e.g. limited and selective memory and systemic biases. The 
majority of empirical work with PROs focuses on the measurement of pain with some 
evidence from fatigue measurement. Whilst most studies focus on symptoms, others 
examine HRQL, adherence and treatment satisfaction. Empirical research suggests a 
lack of correlation between actual experienced symptoms and recalled symptoms, with 
variability in patient attention to the recall period instruction. Recall is signiﬁcantly 
inﬂuenced by the concept being measured and attributes of the patient at the time of 
assessment. The ﬁndings from the research are in line with the FDA concerns and their 
preference for shorter recall periods. CONCLUSIONS: The ﬁnal FDA PRO guidance 
takes a considered approach to PRO recall periods in light of available research. 
Recommendations are presented on how best to select and justify the most appropriate 
recall period for a PRO measure in order to support regulatory review of drug 
approval label claims.
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DETERMINING MISSING DATA RULES FOR PROS: 
ALPHA-IF-ITEM-DELETED
Nelson L, Coon C, Williams V, Price M
RTI Health Solutions, Research Triangle Park, NC, USA
Missing outcomes data in clinical trials can be detrimental to identifying important 
treatment effects because power is reduced and uncertainty is increased. Although 
missingness at the scale level for patient-reported outcomes (PROs) (e.g., due to 
attrition) is a considerable challenge to measurement in longitudinal clinical trials, 
missingness at the item level for PROs (e.g., due to omission) can be more easily 
overcome and a reliable scale score calculated. The FDA PRO Guidance states that 
the maximum tolerable number of missing item-level responses should be determined 
during the instrument development process, but no particular method is advocated, 
and instrument developers often recommend arbitrary guidelines. Although a number 
of methods exist for examining the effect of missing data on scale precision, one 
simple approach is to calculate Cronbach’s coefﬁcient alpha sequentially as each 
item is deleted from the item set. The order in which items are removed from the 
item set is based on deleting the item with the largest contribution to alpha (i.e., 
alpha-if-item-deleted). When Cronbach’s alpha for the set of remaining items falls 
below an a priori identiﬁed threshold (e.g., 0.70), the number of items deleted from 
the scale minus one is the maximum number of responses that can be missing for 
a scale score to be reliably calculated for a subject. We explored this approach with 
several validated instruments and found that the developer’s guidelines are often 
stricter than the alpha-if-item-deleted method. Broader application of the Cronbach’s 
alpha approach would result in fewer missing PRO scale scores, increased statistical 
power, reduced uncertainty, and additional information with which to assess treat-
ment effects.
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TAPPING INTO A NEW DATA COLLECTION PARADIGM: USING 
DIRECT TO PATIENT PROGRAMS FOR MORE COST EFFECTIVE STUDY 
MANAGEMENT
Tandon R
PAREXEL International, Waltham, MA, USA
OBJECTIVES: 1)Understand how to navigate the regulatory environment, manage 
patient safety proﬁles, and achieve optimal process effectiveness in designing a Direct 
to Patient study; 2)Gather information on leveraging integrated technologies to 
support these studies; and 3)Learn key challenges and solutions from early Direct 
to Patient study implementations METHODS: The presentation will outline how to 
best design Direct to Patient studies to collect the right patient outcome data that 
will drive the most useful analysis. The presentation will look at the use of patient 
reported data to drive enrollment at the IND stage. Various methods of collecting 
patient data directly will be reviewed. RESULTS: Many questions are arising as the 
industry embarks on Direct to Patient programs, including how to navigate the 
regulatory challenges and various controls and guidelines. Other issues include how 
to address the changing role of investigators in this study model.Optimal roadmaps 
for designing Direct to Patient studies will be discussed, including the implementation 
of a ﬂexible clinical and medical infrastructure to monitor patient participation. 
Issues such as the shift from site management to patient management, the process 
for management from recruitment to retention, and the processes for adverse event 
follow-up will be discussed. The optimal use of technology, such as portals, Ran-
domization and Trial Supply Management technologies and ePRO data collection 
tools as well as the use of EDC in Direct to Patient programs will be discussed 
along with the right application of web-based and new social media tools. CON-
CLUSIONS: The increased need to have more outcomes and effectiveness data along 
with mounting pressure on the biopharmaceutical industry to contain costs have 
forced companies to look at new ways to manage studies more effectively and 
efﬁciently. There is a trend toward designing studies that reach out to patients 
directly in new ways, while at the same time eliminating costs and intermediaries 
associated with traditional studies.
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INSTIGATING AND ENCOURAGING INDIVIDUAL HEALTH BEHAVIORS 
THROUGH TECHNOLOGY: A TRANSTHEORETICAL PROPOSITION
Ersin ÖH, Freitas EL, Schommer JC
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: The purpose of this conceptual work is to propose a transtheoretical 
framework for the development, selection, and evaluation of consumer technologies 
that promote individual health behaviors. To the best of our knowledge, this work is 
the ﬁrst of its kind to transcend the traditional “informatics/organizational interven-
tions” dyad to suggest, instead, an alternative conceptualization of technology rooted 
in theories of individual health behaviors, and one that acknowledges personal agency 
as a key factor vis a vis consumer technology decisions within the health context. 
CHALLENGE: Consumer technologies represent a hitherto untapped opportunity for 
encouraging afﬁrmative and beneﬁcial health behaviors on the individual level. 
Advances in information technologies including ubiquitous computing, social net-
working, and broadband Internet access have increased the scope and availability of 
health-related information. However, empirical evidence implicates the abundance of 
information sources as culprits in the widening knowledge gap among subpopulations 
of consumers. The relegation of technology to the realm of information-only is equally 
problematic for its presumed bias against uses of technology in “non-informatics” 
contexts, and for its apparent ignorance of the role of consumers as agents of their 
own health behaviors. RECOMMENDATION: We propose the novel application of 
The Transtheoretical Model (TTM) of Behavior Change at the critical intersection of 
consumer technologies and individual health behaviors. As we discuss in our work, 
TTM accommodates a consumer-focused vision of technology that is cognizant of the 
multi-stage, multi-process, and non-linear nature of human action in the context of 
adopting and maintaining health behaviors. We conclude our work with a list of 
principles informed by TTM to guide the development, selection, and evaluation 
of new and innovative technologies that encourage the adoption and maintenance of 
health behaviors by individual consumers.
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PATIENT-REPORTED OUTCOMES IN CLINICAL RESEARCH:  
PRESENT STATUS AND A LOOK TO THE FUTURE
Hao Y
Mapi Values, Boston, MA, USA
A combination of factors have contributed to an increased interest in patient-reported 
outcome (PRO) data. Increased chronic diseases and aging population, empowered 
patient group, a shift of treatment focus from curing diseases to ameliorating symp-
toms, as well as increasing budget constraint and competition among drugs developers 
are among the factors driving an increasing interest in assessing PROs. As the number 
and quantity of PROs increase, quality and criteria to assess these measures as well 
as sources of error and bias are increasingly being emphasized. A series of efforts were 
made in EU and the US to propose criteria for evaluating the scientiﬁc quality of PRO 
data in clinical practice. At the same time, major organizations sought to rationalize 
the ﬁeld and improve the standing of PRO assessments through open communications 
with key regulatory agencies including the FDA and the EMEA. Accordingly, issues 
related to methodological standards for measuring and interpreting PROs in the drug 
evaluation process were debated and the research agenda on PROs were expedited. 
Current major trends in PRO research include computerized adaptive testing (CAT), 
ePROs, and an integrated data collection. The adoption of CAT supported by modern 
psychometrics such as Item Response Theory (IRT) have the potential to achieve far 
greater precision in measuring health outcomes without increasing the response 
burden. However, crucial theoretical and methodological concerns need to be 
addressed before widely applying this approach in patient outcome research. ePROs 
have prevailed in clinical trials and shown high patient acceptance. The advantages 
of ePRO are evident. However, practical issues may be another hurdle before the 
practice is widely accepted in clinical research. Finally, as PRO data collection becomes 
more common in clinical trials, the coordination of integrated data collection may be 
of beneﬁt to all stakeholders.
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EXAMINATION OF THE DIFFERENCES IN PATIENT SATISFACTION 
BETWEEN FIRST VISIT AND RETURN VISITS: ANALYSIS OF A USA 
SELF-REPORTED SURVEY DATA
Iaconi AI1, Chang J1, Feldman SR2, Balkrishnan R1
1The University of Michigan, Ann Arbor, MI, USA, 2Wake Forest University, Winston-Salem, 
NC, USA
OBJECTIVES: Very few studies have attempted to document differences in patient 
satisfaction between ﬁrst and return visits. Therefore, we examined the differences in 
patient satisfaction with their primary care physician at ﬁrst visit compared to return 
visits. METHODS: We conducted a cross-sectional national web based survey study 
consisting of anonymous patients rating their physicians on the basis of treatment 
satisfaction received from their most recent outpatient visit. The user-friendly validated 
survey was designed to help patients identify their physicians as per specialties and 
rate them on a scale of 0 (“not at all satisﬁed”) to 10 (“extremely satisﬁed”). The 
association between satisfaction with primary care physician and patient ratings of 
total care between ﬁrst visit and return visits was accessed using robust regression 
analysis. RESULTS: A total of 9974 patients who rated physicians belonging to the 
categories of ﬁrst visit and return visits were included in this study. Other things being 
equal, return visits have a sizable effect on patient satisfaction. For unit change from 
ﬁrst to return visits the coefﬁcient of patient satisfaction for the return visits was 10.5 
